Strategically, the combined use of inhibitors of YAP and epidermal growth factor receptor (EGFR) targeting the EGFR-PI3K-PDK1 pathway shows improved cytotoxicity for HCC cells (70). This evidence concerns the gene YAP1 and hepatocellular carcinoma.